Analyst firms · BofA Securities · TXG

BofA Securities TXG price target and rating history

10x Genomics Inc. (TXG) · Health Care

BofA Securities rates 10x Genomics Inc. (TXG) Neutral with a $54 price target, as of its latest action on Dec 12, 2023. It has published 3 rating actions on TXG since September 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a TXG price target in the last 12 months, the median target is $69.

Current rating
Neutral
Price target
$54
Median target, all firms
$69
Actions on TXG
3

BofA Securities price target on TXG

$180$108$3520222023202420252026
BofA Securities price target on TXG, each point a stated target, September 2021 to December 2023.

Every BofA Securities rating on TXG

How other firms rate TXG

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StephensEqual-WeightOct 23, 2026
Argus ResearchBuy$110Sep 28, 2026
UBSNeutral$68Sep 9, 2026
RBC Capital MarketsSector Perform$70Sep 1, 2026
William BlairOutperformMar 31, 2026
CitigroupNeutralDec 11, 2025
Morgan StanleyEqual-Weight$20Dec 2, 2025

Questions about BofA Securities and TXG

What is BofA Securities's price target for TXG?
BofA Securities's latest stated price target for 10x Genomics Inc. (TXG) is $54, from its action on Dec 12, 2023.
What is BofA Securities's rating on TXG?
BofA Securities rates TXG Neutral, a neutral rating, as of Dec 12, 2023.
When did BofA Securities last change its view on TXG?
On Dec 12, 2023, BofA Securities upgrades to Neutral from Underperform, price target $36 to $54.
How does BofA Securities's TXG target compare with other analysts?
Across 4 firms with a TXG price target in the last 12 months, the median target is $69.

More TXG rating histories

All BofA Securities ratingsTXG news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.